U.S. Markets open in 42 mins

Synageva BioPharma announces positive results from Phase I/II trial of SBC-102

Synageva BioPharma announced encouraging safety and tolerability data as well as effects consistent with preclinical findings and known mechanism of action. Patients from this 4-week Phase I/II trial of SBC-102 in adults with late onset LAL Deficiency continue to transition into an open-label extension study.